IDSA ATS CAP guidelines. IDSA/ATS guidelines: Recommended empiric antibiotics for community- acquired pneumonia in adults. Outpatient treatment.
![Idsa Guidelines For Community Acquired Pneumonia In Adults Idsa Guidelines For Community Acquired Pneumonia In Adults](http://golfingprofessional.info/wp-content/uploads/2016/07/pneumonia-hospital-ventilator-vent-patient-1080x663.png)
Previously healthy and no use of antimicrobials within the previous three months: A macrolide (azithromycin, clarithromycin, or erythromycin)OR Doxycyline*2. Presence of comorbidities such as chronic heart, lung, liver, or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous three months (in which case an alternative from a different class should be selected): A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [7. OR A beta- lactam (first- line agents: high- dose amoxicillin, amoxicillin- clavulanate; alternative agents: ceftriaxone, cefpodoxime, or cefuroxime) PLUS a macrolide (azithromycin, clarithromycin, or erythromycin)*3. In regions with a high rate (> 2.
Sensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S40. IDSA/ATS Guidelines on Community-Acquired Pneumonia in Adults - PowerPoint PPT Presentation. Community-acquired pneumonia. The IDSA/ATS consensus guidelines on the management of CAP in adults Correspondence.
MIC ≥1. 6 mcg/m. L) macrolide- resistant Streptococcus pneumoniae, consider use of alternative agents listed in (2) above. Inpatients, non- ICU treatment.
Management of Community-Acquired Pneumonia in Adults. • The elderly and/or adults with co-morbid illness. guidelines from the UK.
A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [7. OR An antipneumococcal beta- lactam (preferred agents: cefotaxime, ceftriaxone, or ampicillin- sulbactam; or ertapenem for selected patients)¶PLUS a macrolide (azithromycin, clarithromycin, or erythromycin)*ΔInpatients, ICU treatment. An antipneumococcal beta- lactam (cefotaxime, ceftriaxone, or ampicillin- sulbactam) PLUS azithromycin. ORAn antipneumococcal beta- lactam (cefotaxime, ceftriaxone, or ampicillin- sulbactam) PLUS a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [7. OR For penicillin- allergic patients, a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [7. PLUS aztreonam. Special concerns.
If Pseudomonasaeruginosa is a consideration: An antipneumococcal, antipseudomonal beta- lactam (piperacillin- tazobactam, cefepime, imipenem, or meropenem) PLUS either ciprofloxacin or levofloxacin (7. ORThe above beta- lactam PLUS an aminoglycoside PLUS azithromycin. OR The above beta- lactam PLUS an aminoglycoside PLUS a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [7. If CA- MRSA is a consideration: Add vancomycin or linezolid. This table provides the 2. Infectious Diseases Society of America and the American Thoracic Society for reference purposes.
Refer to the Up. To. Date text for information about choosing between the different guidelines and about the preferred doses and durations of the individual antibiotics.
Reference: File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled- blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community- acquired pneumonia. Clin Infect Dis 2. Modified with permission from: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults.
Clin Infect Dis 2. Suppl 2: S2. 7. Copyright © 2. University of Chicago Press. Graphic 7. 16. 65 Version 1.
Practice Essentials, Overview, Etiology of Community- Acquired Pneumonia. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al.
Community- Acquired Pneumonia Requiring Hospitalization among U. S. Adults. N Engl J Med. Jul 3. 0. 3. 73 (5): 4. Medline]. Musher DM, Thorner AR.
IDSA/ATS Guidelines on Community-Acquired Pneumonia in Adults. Patty W. Wright, MD March 2011. with special thanks to Tom Talbot, MD, MPH. CAP: Objective.
Community- acquired pneumonia. N Engl J Med. 2. 01.
Oct 2. 3. 3. 71 (1. Medline]. Cunha BA. Swine Influenza (H1. N1) Pneumonia: Clinical Considerations. Infect Dis Clin N Am.
Huijskens EG, Koopmans M, Palmen FM, van Erkel AJ, Mulder PG, Rossen JW. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community- acquired pneumonia. J Med Microbiol. 2. Mar. 6. 3 (Pt 3): 4.
Medline]. Boersma WG, Daniels JM, Löwenberg A, Boeve WJ, van de Jagt EJ. Reliability of radiographic findings and the relation to etiologic agents in community- acquired pneumonia. Respir Med. 2. 00.
May. 1. 00(5): 9. Medline]. Bruns AH, Oosterheert JJ, Prokop M, Lammers JW, Hak E, Hoepelman AI.
Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community- acquired pneumonia. Clin Infect Dis. 2.
Oct 1. 5. 4. 5(8): 9. Medline]. [Guideline] Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults.
Clin Infect Dis. 2. Mar 1. 4. 4 Suppl 2: S2. Medline]. Liu JL, Xu F, Hui Zhou, Wu XJ, Shi LX, Lu RQ, et al. Expanded CURB- 6.
Sci Rep. 2. 01. 6 Mar 1. Medline]. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, et al. Antibiotic treatment strategies for community- acquired pneumonia in adults. N Engl J Med. 2. 01. Apr 2. 3. 72 (1. 4): 1. Medline]. Wunderink RG, Waterer GW. Clinical practice.
Community- acquired pneumonia. N Engl J Med. 2. 01. Feb 6. 3. 70 (6): 5. Medline]. Blasi F, Tarsia P. Value of short- course antimicrobial therapy in community- acquired pneumonia.
Int J Antimicrob Agents. Dec. 2. 6 Suppl 3: S1. Medline]. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 7. 50- mg, 5- day levofloxacin in the treatment of community- acquired pneumonia caused by atypical pathogens.
Curr Med Res Opin. Apr. 2. 0(4): 5. 55- 6. Medline]. Harrington Z, Barnes DJ. One drug or two? Step- down therapy after i. Intern Med J. 2. 00. Nov. 3. 7(1. 1): 7.
Medline]. Scalera NM, File TM Jr. How long should we treat community- acquired pneumonia? Curr Opin Infect Dis. Apr. 2. 0(2): 1. 77- 8.
Medline]. Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S, et al. Duration of antibiotic therapy in hospitalised patients with community- acquired pneumonia. Eur Respir J. 2. 01. Jul. 3. 6(1): 1. 28- 3. Medline]. Alvarez- Lerma F, Torres A. Severe community- acquired pneumonia.
Curr Opin Crit Care. Oct. 1. 0(5): 3. 69- 7. Medline]. Brown SM, Jones BE, Jephson AR, Dean NC. Validation of the Infectious Disease Society of America/American Thoracic Society 2. Crit Care Med. 2.
Dec. 3. 7(1. 2): 3. Medline]. [Full Text]. Carron M, Freo U, Zorzi M, Ori C. Predictors of failure of noninvasive ventilation in patients with severe community- acquired pneumonia.
J Crit Care. 2. 01. Sep. 2. 5(3): 5. 40. Medline]. Cunha BA. Severe Community- acquired Pneumoniae in the Critical Care Unit.
Cunha BA (ed). Infectious Disease in Critical Care Medicine. Ed. New York, New York: Informa Healthcare; 2. Nakanishi M, Yoshida Y, Takeda N, Hirana H, Horita T, Shimizu K, et al. Significance of the progression of respiratory symptoms for predicting community- acquired pneumonia in general practice. Respirology. 2. 01.
Aug. 1. 5(6): 9. 69- 7. Medline]. Holter JC, Müller F, Bjørang O, Samdal HH, Marthinsen JB, Jenum PA, et al. Etiology of community- acquired pneumonia and diagnostic yields of microbiological methods: a 3- year prospective study in Norway. BMC Infect Dis. 2. Feb 1. 5. 1. 5: 6. Medline]. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD.
Microbiological profile of community- acquired pneumonia in adults over the last 2. J Infect. 2. 00. 5 Feb. Medline]. Cilloniz C, Ewig S, Ferrer M, et al.
Community acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. Crit Care. 2. 01.
Sep 1. 4. 1. 5(5): R2. Medline]. Burillo A, Bouza E. Chlamydophila pneumoniae. Infect Dis Clin North Am. Mar. 2. 4(1): 6. 1- 7.
Medline]. File TM Jr, Marrie TJ. Burden of community- acquired pneumonia in North American adults. Postgrad Med. 2. 01. Mar. 1. 22(2): 1. Medline]. Fung HB, Monteagudo- Chu MO. Community- acquired pneumonia in the elderly.
Am J Geriatr Pharmacother. Feb. 8(1): 4. 7- 6.
Medline]. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The burden of community- acquired pneumonia in seniors: results of a population- based study. Clin Infect Dis. 2. Dec 1. 3. 9(1. 1): 1.
Medline]. Mc. Laughlin JM, Johnson MH, Kagan SA, Baer SL. Clinical and economic burden of community- acquired pneumonia in the Veterans Health Administration, 2. Infection. 2. 01. Dec. 4. 3 (6): 6. Medline]. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine. 2. 01. 5 Jun 2.
Medline]. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishii M, Hibi S, et al. Lower respiratory tract infection outcomes are predicted better by an age > 8. CURB- 6. 5. Eur Respir J. Feb. 3. 1 (2): 4. Medline]. Marrie TJ, Poulin- Costello M, Beecroft MD, Herman- Gnjidic Z.
Etiology of community- acquired pneumonia treated in an ambulatory setting. Respir Med. 2. 00. Jan. 9. 9(1): 6. 0- 5. Medline]. Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A. Etiology and outcome of community- acquired pneumonia in patients with diabetes mellitus. Chest. 2. 00. 5 Nov. Medline]. Baum S.
Mycoplasma pneumoniae and atypical pneumonia. Mandell, Bennett, & Dolin, eds. Principles and Practice of Infectious Diseases. Churchill Livingstone; 2. Chapter 1. 85. Cunha BA, Burillo A, Bouza E.
Legionnaires' disease. Lancet. 2. 01. 6 Jan 2. Medline]. Anderson A, Bijlmer H, Fournier PE, Graves S, Hartzell J, Kersh GJ, et al. Diagnosis and management of Q fever- -United States, 2.
CDC and the Q Fever Working Group. MMWR Recomm Rep. 2. Mar 2. 9. 6. 2 (RR- 0. Medline]. Marrie TJ, Raoult D.
Coxiella burnetti (Q fever). Mandell G, Bennett.
J, Dolin R, eds. PPID. Churchill Livingstone; 2. Chapter 1. 89. Galetto- Lacour A, Alcoba G, Posfay- Barbe KM, Cevey- Macherel M, Gehri M, Ochs MM, et al. Elevated Inflammatory Markers Combined with Positive Pneumococcal Urinary Antigen are a Good Predictor of Pneumococcal Community Acquired Pneumonia in Children. Pediatr Infect Dis J.
May 2. 0. [Medline]. Giulia B, Luisa A, Concetta S, Bruna LS, Chiara B, Marcello C.
Procalcitonin and community- acquired pneumonia (CAP) in children. Clin Chim Acta. 2. Dec 7. 4. 51 (Pt B): 2. Medline]. Loens K, Ieven M.
Mycoplasma pneumoniae: Current Knowledge on Nucleic Acid Amplification Techniques and Serological Diagnostics. Front Microbiol. 2. Medline]. Harris AM, Beekmann SE, Polgreen PM, Moore MR. Rapid urine antigen testing for Streptococcus pneumoniae in adults with community- acquired pneumonia: clinical use and barriers.
Diagn Microbiol Infect Dis. Aug. 7. 9 (4): 4. Medline]. Huijskens EG, Rossen JW, Kluytmans JA, van der Zanden AG, Koopmans M. Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community- acquired pneumonia. Influenza Other Respir Viruses.
Mar. 8 (2): 2. 43- 9. Medline]. Gadsby NJ, Russell CD, Mc. Hugh MP, Mark H, Conway Morris A, Laurenson IF, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community- Acquired Pneumonia.
Clin Infect Dis. 2. Apr 1. 6. 2 (7): 8. Medline]. Davydov L, Ebert SC, Restino M, Gardner M, Bedenkop G, Uchida KM. Prospective evaluation of the treatment and outcome of community- acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals. Diagn Microbiol Infect Dis. Apr. 5. 4(4): 2. 67- 7. Medline]. Fishbane S, Niederman MS, Daly C, Magin A, Kawabata M, de Corla- Souza A.
The impact of standardized order sets and intensive clinical case management on outcomes in community- acquired pneumonia. Arch Intern Med. 2. Aug 1. 3- 2. 7. 1. Medline]. Marrie TJ, Huang JQ.
Low- risk patients admitted with community- acquired pneumonia. Am J Med. 2. 00. 5 Dec. Medline]. Marrie TJ, Shariatzadeh MR. Community- acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore). Mar. 8. 6(2): 1. 03- 1.
Medline]. Yoshimoto A, Nakamura H, Fujimura M, Nakao S. Severe community- acquired pneumonia in an intensive care unit: risk factors for mortality. Intern Med. 2. 00. Jul. 4. 4(7): 7. 10- 6.
Medline]. Genné D, Sommer R, Kaiser L, Saaïdia A, Pasche A, Unger PF. Analysis of factors that contribute to treatment failure in patients with community- acquired pneumonia. Eur J Clin Microbiol Infect Dis. Mar. 2. 5(3): 1. 59- 6.
Medline]. Siemieniuk RA, Meade MO, Alonso- Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community- Acquired Pneumonia: A Systematic Review and Meta- analysis. Ann Intern Med. 2.
Oct 6. 1. 63 (7): 5. Medline]. Restrepo MI, Anzueto A, Torres A. Corticosteroids for Severe Community- Acquired Pneumonia: Time to Change Clinical Practice.
Ann Intern Med. 2. Oct 6. 1. 63 (7): 5. Medline]. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community- acquired pneumonia: a randomized double- blinded clinical trial.
Am J Respir Crit Care Med. May 1. 1. 81 (9): 9. Medline]. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community- acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2. 01. 5 Feb 1.